Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)

NCT00494091 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00494091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
March 31, 2012
Enrollment
82 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma